Unichem Laboratories Ltd. (BSE: 506690) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹3,501 Cr, it ranks #990 by market cap among the 6,197 Indian listed companies on FinBizNet, and #32 of 86 in Medicinal Chemicals and Botanical Products. At ₹500.20 (as of 16 Nov 2026), the share price is 27.2% below its 52-week high of ₹687.20 and 79.8% above its 52-week low of ₹278.20. The share price is up 8.4% over one year and down 8.0% over three months.
| Current Price | ₹500.20 |
|---|---|
| Market Cap | ₹3,501 Cr |
| BSE Code | 506690 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 13.8 |
| Return on Equity | 9.78% |
| Return on Assets | 1.09% |
| 52-Week Range | ₹278.20 – ₹687.20 |
| 1-Year Price Change | +8.4% |
| 3-Month Price Change | -8.0% |
| Beta (1Y) | 0.25 |
| Dividend Yield | 0.00% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.unichemlabs.com |
| Revenue | ₹640 Cr |
|---|---|
| Net Profit | ₹22 Cr |
| Net Margin | 3.5% |
| EPS (Basic) | ₹3.16 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Unichem Laboratories Ltd. reported revenue of ₹640 Cr in Q2 FY27, up 10.6% from ₹579 Cr in Q2 FY26 and up 1.2% from ₹633 Cr in Q1 FY27. It posted a net profit of ₹22 Cr for the quarter, against a net loss of ₹12 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹521 Cr (Q3 FY26) to ₹640 Cr (Q2 FY27). The company reported a net loss in 2 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹640 Cr | ₹22 Cr | 3.5% |
| Q1 FY27 | ₹633 Cr | ₹41 Cr | 6.6% |
| Q4 FY26 | ₹575 Cr | ₹11 Cr | 1.9% |
| Q3 FY26 | ₹521 Cr | ₹264 Cr | 50.7% |
| Q2 FY26 | ₹579 Cr | −₹12 Cr | −2.1% |
| Q1 FY26 | ₹527 Cr | −₹10 Cr | −2.0% |
| Q4 FY25 | ₹587 Cr | ₹53 Cr | 9.0% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 70.22% of Unichem Laboratories Ltd.'s shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 37.3% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products in India, the United States, and internationally. The company offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management. It also offers active pharmaceutical ingredients, as well as contract manufacturing services. In addition, the company manufactures allopathic medicines, bulk drugs, and chemicals. It serves patients, distributors, health care professionals, and government institutions. The company was founded in 1944 and is based in Mumbai, India. Unichem Laboratories Limited is a subsidiary of Ipca Laboratories Limited.
1. Pharmaceuticals-This segment manufactures and sells pharmaceutical products.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Unichem Laboratories Ltd. | ₹3,501 Cr | 13.8 | 9.78% | ₹640 Cr | +8.4% |
Listed by market capitalisation. Ratios are shown for context only.
Unichem Laboratories Ltd. is trading at ₹500.20, with a market capitalisation of ₹3,501 Cr.
Unichem Laboratories Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Unichem Laboratories Ltd. has a P/E of 13.8 and a return on equity of 9.78%.
Unichem Laboratories Ltd. is listed on the BSE under the scrip code 506690.
Unichem Laboratories Ltd.'s share price is up 8.4% over one year and down 8.0% over three months. Its 52-week range is ₹278.20 to ₹687.20.
In Q2 FY27, Unichem Laboratories Ltd. reported revenue of ₹640 Cr and net profit of ₹22 Cr, with basic EPS of ₹3.16 (consolidated, parsed from the company's exchange filing).
Unichem Laboratories Ltd. reported revenue of ₹640 Cr in Q2 FY27, up 10.6% from ₹579 Cr in Q2 FY26 and up 1.2% from ₹633 Cr in Q1 FY27.
Promoters held 70.22% of Unichem Laboratories Ltd.'s shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.